^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LBA4 - Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced nonsquamous NSCLC in KEYNOTE-042
Published date:
12/12/2019
Excerpt:
Outcomes of pembrolizumab and of chemotherapy for pts with and without KRAS mutation and for KRAS G12C carriers are in the Table. Of note, CIs were wide given the modest frequency of KRAS mutation and low frequency of KRAS G12C...These findings also suggest that a pembrolizumab-containing regimen is a clinically relevant comparator for studies of KRAS -targeted therapy given as first-line treatment of NSCLC.
Trial ID:
Source:
Title:
A study investigating the use of IO102-IO103 in combination with pembrolizumab for patients with metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or metastatic Urothelial Bladder Cancer (mUBC)
Excerpt:
...Patients with histologically or cytologically confirmed:Metastatic NSCLC (adenocarcinoma) (Arm A), who have not received prior systemic treatment for their metastatic disease and who have:• no known sensitizing genetic aberrations where there are approved therapies (such as EGFR, KRAS G12C, BRAF V600E, MET skipping mutations, and RET mutations or rearrangements)orMetastatic SCCHN (Arm B) with no prior therapy and who have:• Histologically- or cytologically-confirmed recurrent (without metastases) or metastatic SCCHN considered incurable by local therapies. ...
Trial ID:
Source:
Title:
P59.25 - Prognostic and Treatment Characteristics of Metastatic KRAS G12C Mutant NSCLC
Published date:
08/18/2021
Excerpt:
102 KRASG12C+ patients were identified....Overall 15% (15/102) of KRASG12C+ had second-line SACT for progressive disease….Among the SACT group, the median OS was 19.7 months.
